| Literature DB >> 30899732 |
Abstract
It still remains controversial whether exercise will help or adversely affect the bone formation. The aim of this study was to evaluate the effect of common long-distance running on the magnitude of change in bone properties as measured by quantitative ultrasound (QUS) and bone biochemical markers. Subjects included 68 long-distance runners and 40 controls. Long-distance runners had been training in the marathon club for at least 6 months, the average period of exercise was 2 years, and running at 48.6±24.9 km per week. Otherwise, controls were people who had not experienced any specific sports before. Bone speed of sound (SOS) was measured by QUS at the distal one third radius and the mid-shaft of the tibia. Serum osteocalcin and urine deoxypyridinolin were measured in all groups. No significant differences were found in tibial and radial SOS between the two groups. Serum osteocalcin was higher in long-distance runners than control (P<0.05) in both the 30s and 40s of the participants, but urine deoxypyridinolin showed no significant difference between the two groups. It is concluded that long-distance running at the club level increases bone formation marker, but seems to do no harmful effect on bone properties as measured by QUS.Entities:
Keywords: De-oxypyridinolin; Long-distance runners; Osteocalcin; Speed of sound
Year: 2019 PMID: 30899732 PMCID: PMC6416492 DOI: 10.12965/jer.1836564.282
Source DB: PubMed Journal: J Exerc Rehabil ISSN: 2288-176X
Training characteristics in marathoners
| Variable | Mean±SD | Range |
|---|---|---|
| Period of exercise (mo) | 25.9±13.1 | 6–60 |
| Running distance per week (km) | 48.6±24.9 | 30–80 |
| Frequency per week | 4.4±1.8 | 1–7 |
SD, standard deviation.
Fig. 1Mean tibial speed of sound in the marathoner and control.
Fig. 2Mean raidal speed of sound in the marathoner and control.
The concentration of serum osteocalcin (ng/mL)
| Age (yr) | Male | Female | ||
|---|---|---|---|---|
|
|
| |||
| Marathoner | Control | Marathoner | Control | |
| 30–39 | 11.2±4.1 | 7.0±2.0 | 11.6±4.9 | 5.0±2.4 |
|
| ||||
| 40–49 | 11.8±4.8 | 7.1±1.8 | 10.3±4.0 | 6.5±2.9 |
Values are presented as mean±standard deviation.
P<0.05.
The concentration of urine deoxypyridinolin (nmol/nmol Cr)
| Age (yr) | Male | Female | ||
|---|---|---|---|---|
|
|
| |||
| Marathoner | Control | Marathoner | Control | |
| 30–39 | 2.9±1.3 | 3.2±1.4 | 4.9±2.6 | 5.8±3.3 |
|
| ||||
| 40–49 | 2.9±1.6 | 2.0±1.5 | 4.0±0.8 | 5.3±2.6 |
Values are presented as mean±standard deviation.